FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Equine Vet J / Lumbar vertebral bone density is decreased in horses with pi...
Equine veterinary journal2023; 56(2); 368-376; doi: 10.1111/evj.14039

Lumbar vertebral bone density is decreased in horses with pituitary pars intermedia dysfunction.

Abstract: Pathological fractures have been reported in equids with pituitary pars intermedia dysfunction (PPID) but their prevalence and pathogenesis is unknown. Objective: To compare: (1) bone mineral density (BMD) in weight bearing and nonweight bearing bones in PPID+ equids and aged and young PPID- controls; and (2) biomechanical properties of the fourth lumbar vertebral body in PPID+ equids and aged PPID- equids. Methods: Case-control study: five PPID+ equids and six aged and four young PPID- control horses. Methods: PPID status was based on clinical signs and necropsy examination of the pituitary gland (PG). The lumbar vertebral column, right front third metacarpus (MC3), left hind third metatarsus (MT3), and PG were removed after euthanasia. BMD was determined by quantitative computed tomography of regions of interest (ROI) in each bone and biomechanical testing was performed on the fourth lumbar vertebral body. Serum concentrations of parathormone (PTH), ionised Ca++ , 25-hydroxyvitamin D, and osteocalcin (OC) were also measured. Data were analysed using one-way ANOVA and correlation analyses. Results: BMD of trabecular and cortical regions of interest (ROI) of the third, fourth (L4), and fifth lumbar vertebrae were significantly lower in PPID+ equids as compared with aged (p < 0. 001) and young (p < 0.01) PPID- controls. In contrast, no differences were found in BMD of trabecular or cortical ROIs of MC3 and MT3 between groups. No differences were detected in force at fracture, displacement at fracture, Young's modulus or strain of L4 between PPID+ and aged PPID- horses. No differences were found in serum PTH, ionised Ca++ , 25-hydroxyvitamin D, or OC concentrations between groups. Conclusions: Limited number of equids studied and variation in test results. Conclusions: BMD of nonweight bearing bones can be decreased with PPID and could increase risk of developing pathological fractures.
© 2023 The Authors. Equine Veterinary Journal published by John Wiley & Sons Ltd on behalf of EVJ Ltd.
Get Full Text
Publication Date: 2023-12-27 PubMed ID: 38151767DOI: 10.1111/evj.14039Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research investigates vertebral bone density in horses affected by pituitary pars intermedia dysfunction (PPID) and how it might affect risks of developing pathological fractures.

Study Purpose and Design

  • This study is a comparative case-control research aimed at comparing bone mineral density (BMD) and biomechanical properties in both weight-bearing and non-weight-bearing bones in equids with PPID and aged as well as young PPID control horses. The purpose is to understand the relationship between PPID and potentially elevated risk of fractures.

Participants and Methods

  • The study involved five PPID equids (horses, donkeys, zebras, and other horse-like animals). For controls, six aged and four young horses with PPID were used.
  • The status of PPID was based on clinical signs and post-mortem examination of the pituitary gland.
  • Bone mineral density was determined using quantitative computed tomography (CT Scan) targeting selected regions in each bone.
  • Biomechanical properties of the fourth lumbar vertebral body were investigated, determining the force required to fracture the bone, and measuring its displacement during that process.
  • Researches also measured concentrations of parathormone (PTH), ionised Calcium, 25-hydroxyvitamin D, and osteocalcin (OC) in serum; these are widely known markers for bone metabolism.
  • The data obtained was scrutinized using one-way ANOVA (for comparisons of group means) and correlation analyses.

Findings

  • The primary finding was that the bone mineral density in weight-bearing vertebrae was significantly lower in PPID equids compared with the control groups.
  • More specifically, BMD of the trabecular and cortical regions in the third, fourth, and fifth lumbar vertebrae were significantly lower in horses with PPID when compared to the control group.
  • However, no difference was noted in the bone mineral density in non-weight bearing bones (MC3 and MT3) among different groups.
  • Moreover, the study did not find any significant difference in the force at fracture, displacement, Young’s modulus, or strain of the lumbar vertebral body between PPID equids and aged control group.
  • The study also found no differences in the serum concentrations of PTH, ionized Calcium, 25-hydroxyvitamin D, or OC between groups, implying that these may not directly relate to the decrease in BMD.

Limitations and Conclusions

  • The limitations involved the small number of equids used in the study and variations in the test results. Despite these limitations, this study provides valuable insights into the implications of PPID on bone health in equids.
  • The primary conclusion drawn is that bone mineral density in non-weight-bearing bones could decrease in horses with PPID, potentially increasing the risk of developing pathological fractures.

Cite This Article

APA
Colbath AC, Fortin JS, Burglass CM, Panek C, Vergara-Hernandez FB, Johnson TN, Robison CA, Logan AA, Nelson NA, Nielsen BD, Schott HC. (2023). Lumbar vertebral bone density is decreased in horses with pituitary pars intermedia dysfunction. Equine Vet J, 56(2), 368-376. https://doi.org/10.1111/evj.14039

Publication

Equine veterinary journal
ISSN: 2042-3306
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 56
Issue: 2
Pages: 368-376

Researcher Affiliations

Colbath, Aimee C
  • Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA.
Fortin, Jessica S
  • Pathobiology and Diagnostic Investigation, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
Burglass, Caroline M
  • Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.
Panek, Char
  • Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, New York, USA.
Vergara-Hernandez, Fernando B
  • Animal Sciences, College of Agriculture and Natural Resources, Michigan State University, East Lansing, Michigan, USA.
Johnson, Tyler N
  • Chemical Engineering and Materials Science, College of Engineering, Michigan State University, East Lansing, Michigan, USA.
Robison, Cara A
  • Animal Sciences, College of Agriculture and Natural Resources, Michigan State University, East Lansing, Michigan, USA.
Logan, Alyssa A
  • Animal Sciences, College of Agriculture and Natural Resources, Michigan State University, East Lansing, Michigan, USA.
Nelson, Nathan A
  • Molecular Biologic Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
Nielsen, Brian D
  • Animal Sciences, College of Agriculture and Natural Resources, Michigan State University, East Lansing, Michigan, USA.
Schott, Harold C
  • Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, Michigan, USA.

MeSH Terms

  • Horses
  • Animals
  • Lumbar Vertebrae / pathology
  • Case-Control Studies
  • Bone Density
  • Fractures, Spontaneous / pathology
  • Fractures, Spontaneous / veterinary
  • Pituitary Gland, Intermediate / pathology
  • Pituitary Diseases / veterinary
  • Pituitary Diseases / diagnosis
  • Horse Diseases / diagnosis

Grant Funding

  • RC110276 / ACVIM RESIDENT RESEARCH AWARD
  • RH082218 / Michigan State University Endowed Research Fund

References

This article includes 32 references
  1. Schott HC. Pituitary pars intermedia dysfunction: equine Cushing's disease. Vet Clin North Am Equine Pract 2002;18:237-270.
    doi: 10.1016/s0749-0739(02)00018-4google scholar: lookup
  2. McFarlane D. Equine pituitary pars intermedia dysfunction. Vet Clin North Am Equine Pract 2011;27:93-113.
    doi: 10.1016/j.cveq.2010.12.007google scholar: lookup
  3. Kirkwood NC, Hughes KJ, Stewart AJ. Pituitary pars intermedia dysfunction (PPID) in horses. Vet Sci 2022;9:556.
    doi: 10.3390/vetsci9100556google scholar: lookup
  4. Morgan RA, Keen JA, Homer N, Nixon M, McKinnon-Garvin AM, Moses-Williams JA. Dysregulation of cortisol metabolism in equine pituitary pars intermedia dysfunction. Endocrinology 2018;159:3791-3800.
    doi: 10.1210/en.2018-00726google scholar: lookup
  5. Cordero M, Shrauner B, McFarlane D. Bioactivity of plasma ACTH from horses with PPID compared to normal horses. J Vet Intern Med 2011;25:664.
  6. Schwarz T, Störk CK, Mellor D, Sullivan M. Osteopenia and other radiographic signs in canine hyperadrenocorticism. J Small Anim Pract 2000;41:491-495.
    doi: 10.1111/j.1748-5827.2000.tb03970.xgoogle scholar: lookup
  7. Lee D, Lee Y, Choi W, Chang J, Kang J-H. Quantitative CT assessment of bone mineral density in dogs with hyperadrenocorticism. J Vet Sci 2015;16:531-542.
    doi: 10.4142/jvs.2015.16.4.531google scholar: lookup
  8. Hu K, Adachi JD. Glucocorticoid induced osteoporosis. Expert Rev Endocrinol Metab 2019;14:259-266.
    doi: 10.1080/17446651.2019.1617131google scholar: lookup
  9. Shane E, Rivas MC, Silverberg SJ, Kim TS, Staron RB, Bilezikian JP. Osteoporosis after cardiac transplantation. Am J Med 1993;94:257-264.
    doi: 10.1016/0002-9343(93)90057-vgoogle scholar: lookup
  10. King JM, Kavanaugh JF, Bentinck-Smith J. Diabetes mellitus with pituitary neoplasms in a horse and a dog. Cornell Vet 1962;52:133-145.
  11. Loeb WF, Capen CC, Johnson LE. Adenomas of the pars intermedia associated with hyperglycemia and glycosuria in two horses. Cornell Vet 1966;56:623-639.
  12. Boujon CE, Bestetti GE, Meier HP, Straub R, Junker U, Rossi GL. Equine pituitary adenoma: a functional and morphological study. J Comp Pathol 1993;109:163-178.
    doi: 10.1016/s0021-9975(08)80260-5google scholar: lookup
  13. van der Kolk JH, Kalsbeek HC, van Garderen E, Wensing T, Breukink HJ. Equine pituitary neoplasia: a clinical report of 21 cases (1990-1992). Vet Rec 1993;133:594-597.
  14. Schott HC, Nelson NA. Metacarpal bone thickness and density in aged horses with and without pituitary pars intermedia dysfunction. J Vet Intern Med 2018;32:41-42.
    doi: 10.1002/jvim.15314google scholar: lookup
  15. Henneke DR, Potter GD, Kreider JL, Yeates BF. Relationship between condition score, physical measurements and body fat percentage in mares. Equine Vet J 1983;15:371-372.
    doi: 10.1111/j.2042-3306.1983.tb01826.xgoogle scholar: lookup
  16. [Cited 2023 June 10]. Available from: https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/890
  17. Miller MA, Pardo ID, Jackson LP, Moore GE, Sojka JE. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction. Vet Pathol 2008;45:26-38.
    doi: 10.1354/vp.45-1-26google scholar: lookup
  18. Beech J, Boston R, Lindborg S, Russell GE. Adrenocorticotropin concentration following administration of thyrotropin-releasing hormone in healthy horses and those with pituitary pars intermedia dysfunction and pituitary gland hyperplasia. J Am Vet Med Assoc 2007;231:417-426.
    doi: 10.2460/javma.231.3.417google scholar: lookup
  19. Frisbie DD, McIlwraith CW, Arthur RM, Blea J, Baker VA, Billinghurst RC. Serum biomarker levels for musculoskeletal disease in two- and three-year-old racing thoroughbred horses: a prospective study of 130 horses. Equine Vet J 2010;42:643-651.
    doi: 10.1111/j.2042-3306.2010.00123.xgoogle scholar: lookup
  20. Logan AA, Nielsen BD, Robison CI, Manfredi JM, Buskirk DD, Schott HC. Calves, as a model for juvenile horses, need only one sprint per week to experience increased bone strength. J Anim Sci 2019;97:3300-3312.
    doi: 10.1093/jas/skz202google scholar: lookup
  21. Robison CI, Karcher DM. Analytical bone calcium and bone ash from mature laying hens correlates to bone mineral content calculated from quantitative computed tomography scans. Poult Sci 2019;98:3611-3616.
    doi: 10.3382/ps/pez165google scholar: lookup
  22. Chen W, Lu F, Winfree N. High-strain-rate compressive behavior of a rigid polyurethane foam with various densities. Exp Mech 2002;42:65-73.
    doi: 10.1007/bf02411053google scholar: lookup
  23. Peng CH, Lin WY, Yeh KT, Chen I-H, Wu W-T, Lin M-D. The molecular etiology and treatment of glucocorticoid-induced osteoporosis. Tzu Chi Med J 2021;33:212-223.
    doi: 10.4103/tcmj.tcmj_233_20google scholar: lookup
  24. Compston J. Glucocorticoid-induced osteoporosis: an update. Endocrine 2018;61:7-16.
    doi: 10.1007/s12020-018-1588-2google scholar: lookup
  25. Bonnick SL, Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am J Med 2006;119(4 Suppl 1):S25-S31.
    doi: 10.1016/j.amjmed.2005.12.020google scholar: lookup
  26. Gilsanz V, Perez FJ, Campbell PP, Dorey FJ, Lee DC, Wren TAL. Quantitative CT reference values for vertebral trabecular bone density in children and young adults. Radiology 2009;250:222-227.
    doi: 10.1148/radiol.2493080206google scholar: lookup
  27. Lane NE. Glucocorticoid-induced osteoporosis: new insights into the pathophysiology and treatments. Curr Osteoporos Rep 2019;17:1-7.
    doi: 10.1007/s11914-019-00498-xgoogle scholar: lookup
  28. Ireland JL, McGowan CM. Epidemiology of pituitary pars intermedia dysfunction: a systematic literature review of clinical presentation, disease prevalence and risk factors. Vet J 2018;235:22-33.
    doi: 10.1016/j.tvjl.2018.03.002google scholar: lookup
  29. Clegg A, Hassan-Smith Z. Frailty and the endocrine system. Lancet Diabetes Endocrinol 2018;6:743-752.
    doi: 10.1016/s2213-8587(18)30110-4google scholar: lookup
  30. Kweon SH, Park JS, Park BH. Sarcopenia and its association with change of bone mineral density and functional outcome in old-aged hip arthroplasty patients. Geriatr Orthop Surg Rehabil 2022;13:21514593221092880.
    doi: 10.1177/21514593221092880google scholar: lookup
  31. Banse HE, Whitehead AE, McFarlane D, Chelikani PK. Markers of muscle atrophy and impact of treatment with pergolide in horses with pituitary pars intermedia dysfunction and muscle atrophy. Domest Anim Endocrinol 2021;76:106620.
  32. McGowan CM, Ireland JL. Equine endocrine disease: challenges with case definition for research. J Equine Vet 2023;124:104491.
    doi: 10.1016/j.jevs.2023.104491google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.